Immune checkpoint blockade therapy for cancer is promising, but delivery optimization is desirable. Here the authors generate cancer-targeting liposomes with anti-PD-L1 and doxorubicin for protease-mediated intratumoral release of both components, and see effective tumor control in mouse models, thereby hinting potential clinical translation.
- Yixuan Liu
- Ying Xie
- Wanliang Lu
